Pacific Biosciences of California, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Pacific Biosciences of California, Inc. (PACB) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $1.10 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2024-11-12
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-09-30 was $1.17M.
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-03-31 was -$70.00K, a 100.57% decline year-over-year.
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-12-31 was $1.10M.
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $15.06M.
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2019 was $16.00K, a 90.42% decline from fiscal 2018.
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was $167.00K.
- Pacific Biosciences of California, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was -$653.00K, a 367.62% decline from fiscal 2016.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2024-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.17M derived: sum of 2 quarters · filed 2024-11-12 | $1.10M 10-Q · filed 2024-11-12 | $2.20M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$70.00K 10-Q · filed 2024-08-09 | $1.03M derived: sum of 3 quarters · filed 2024-08-09 | $759.00K derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | -$70.00K 10-Q · filed 2024-05-09 | $1.03M derived: sum of 2 quarters · filed 2024-05-09 | $759.00K derived: sum of 3 quarters · filed 2024-05-09 | $2.73M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $829.00K derived: sum of 2 quarters · filed 2024-02-28 | $2.80M derived: sum of 3 quarters · filed 2024-02-28 | $15.06M 10-K · filed 2024-02-28 |
| 2023-09-30 | -$271.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.70M derived: sum of 2 quarters · filed 2023-11-03 | $13.96M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $14.23M 10-Q · filed 2023-08-04 | ||
| 2023-03-31 | $12.26M 10-Q · filed 2023-05-04 | |||
| 2019-12-31 | $16.00K 10-K · filed 2020-02-28 | |||
| 2018-12-31 | $167.00K 10-K · filed 2020-02-28 | |||
| 2017-12-31 | -$653.00K 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $244.00K 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |